FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387326095> ?p ?o ?g. }

• W4387326095 endingPage "206" @default.
• W4387326095 startingPage "198" @default.
• W4387326095 abstract "Clinical treatment with the antineoplastic drug irinotecan (IRI) is often hindered by side effects that significantly reduce the quality of life of treated patients. Due to the growing public support for products with Δ9-tetrahydrocannabinol (THC), even though relevant scientific literature does not provide clear evidence of their high antitumour potential, some cancer patients take unregistered preparations containing up to 80 % THC. This study was conducted on a syngeneic colorectal cancer mouse model to test the efficiency and safety of concomitant treatment with IRI and THC. Male BALB/c mice subcutaneously injected with CT26 cells were receiving 60 mg/kg of IRI intraperitoneally on day 1 and 5 of treatment and/or 7 mg/kg of THC by gavage a day for 7 days. Treatment responses were evaluated based on changes in body, brain, and liver weight, tumour growth, blood cholinesterase activity, and oxidative stress parameters. Irinotecan's systemic toxicity was evidenced by weight loss and high oxidative stress. The important finding of this study is that combining THC with IRI diminishes IRI efficiency in inhibiting tumour growth. However, further studies, focused on more subtle molecular methods in tumour tissue and analytical analysis of IRI and THC distribution in tumour-bearing mice, are needed to prove our observations.Kliničko liječenje antineoplastičnim lijekom irinotekanom (IRI) često je otežano nuspojavama koje značajno smanjuju kvalitetu života liječenih bolesnika. Zbog sve veće javne potpore proizvodima s Δ9-tetrahidrokanabinolom (THC), iako relevantna znanstvena literatura ne daje jasne dokaze o njihovu visokom antitumorskom potencijalu, oboljeli od raka uzimaju neregistrirane pripravke koji sadržavaju i do 80 % THC-a. Ova studija provedena je na modelu singeničnoga tumora debelog crijeva u miševa kako bi se testirala učinkovitost i sigurnost istodobnog tretmana irinotekanom i THC-om. Mužjaci BALB/c miševa kojima su supkutano injicirane CT26 stanice primili su 60 mg/kg IRI-ja intraperitonealno prvi i peti dan i/ili 7 mg/kg THC-a oralno svaki dan tijekom sedam dana. Učinkovitost tretmana procijenjena je na temelju promjena u težini tijela, mozga i jetre, rasta tumora, aktivnosti kolinesteraza u krvi i parametara oksidacijskoga stresa. Sistemska toksičnost irinotekana potvrđena je smanjenjem težine miševa i povećanjem parametara oksidacijskoga stresa. Značaj je rezultata ove studije u smanjenoj učinkovitosti IRI-ja u inhibiciji rasta tumora tijekom istodobnog uzimanja s THC-om. Međutim, potrebna su daljnja istraživanja usmjerena na suptilnije molekularne metode u tumorskom tkivu i analitička analiza distribucije IRI-ja i THC-a u miševa s tumorom kako bi se dokazala naša opažanja." @default.
• W4387326095 created "2023-10-05" @default.
• W4387326095 creator A5001800305 @default.
• W4387326095 creator A5021054297 @default.
• W4387326095 creator A5025645706 @default.
• W4387326095 creator A5030559629 @default.
• W4387326095 creator A5055750172 @default.
• W4387326095 creator A5068794009 @default.
• W4387326095 creator A5081544780 @default.
• W4387326095 creator A5087420317 @default.
• W4387326095 creator A5092999109 @default.
• W4387326095 date "2023-09-01" @default.
• W4387326095 modified "2023-10-17" @default.
• W4387326095 title "Effects of concomitant use of THC and irinotecan on tumour growth and biochemical markers in a syngeneic mouse model of colon cancer" @default.
• W4387326095 cites W126890223 @default.
• W4387326095 cites W1434138403 @default.
• W4387326095 cites W1570257147 @default.
• W4387326095 cites W1571533074 @default.
• W4387326095 cites W1670328913 @default.
• W4387326095 cites W1777256341 @default.
• W4387326095 cites W1970179483 @default.
• W4387326095 cites W1971048984 @default.
• W4387326095 cites W1983310681 @default.
• W4387326095 cites W1984587843 @default.
• W4387326095 cites W2008090904 @default.
• W4387326095 cites W2011909208 @default.
• W4387326095 cites W2026279850 @default.
• W4387326095 cites W2032116258 @default.
• W4387326095 cites W2059038395 @default.
• W4387326095 cites W2065235584 @default.
• W4387326095 cites W2075602518 @default.
• W4387326095 cites W2088953298 @default.
• W4387326095 cites W2106954948 @default.
• W4387326095 cites W2115524406 @default.
• W4387326095 cites W2117210765 @default.
• W4387326095 cites W2121666688 @default.
• W4387326095 cites W2124319487 @default.
• W4387326095 cites W2131992050 @default.
• W4387326095 cites W2143209864 @default.
• W4387326095 cites W2154901456 @default.
• W4387326095 cites W2168641756 @default.
• W4387326095 cites W2169754532 @default.
• W4387326095 cites W2170902146 @default.
• W4387326095 cites W2253355615 @default.
• W4387326095 cites W2282487911 @default.
• W4387326095 cites W2347042996 @default.
• W4387326095 cites W2607412152 @default.
• W4387326095 cites W2737066334 @default.
• W4387326095 cites W2799429339 @default.
• W4387326095 cites W2805759847 @default.
• W4387326095 cites W2808249144 @default.
• W4387326095 cites W2859836197 @default.
• W4387326095 cites W2887320972 @default.
• W4387326095 cites W2887619760 @default.
• W4387326095 cites W2989864139 @default.
• W4387326095 cites W3005689864 @default.
• W4387326095 cites W3013837660 @default.
• W4387326095 cites W3018437359 @default.
• W4387326095 cites W3040213957 @default.
• W4387326095 cites W3138956198 @default.
• W4387326095 cites W4200364904 @default.
• W4387326095 cites W4309852182 @default.
• W4387326095 cites W63969268 @default.
• W4387326095 doi "https://doi.org/10.2478/aiht-2023-74-3765" @default.
• W4387326095 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37791673" @default.
• W4387326095 hasPublicationYear "2023" @default.
• W4387326095 type Work @default.
• W4387326095 citedByCount "0" @default.
• W4387326095 crossrefType "journal-article" @default.
• W4387326095 hasAuthorship W4387326095A5001800305 @default.
• W4387326095 hasAuthorship W4387326095A5021054297 @default.
• W4387326095 hasAuthorship W4387326095A5025645706 @default.
• W4387326095 hasAuthorship W4387326095A5030559629 @default.
• W4387326095 hasAuthorship W4387326095A5055750172 @default.
• W4387326095 hasAuthorship W4387326095A5068794009 @default.
• W4387326095 hasAuthorship W4387326095A5081544780 @default.
• W4387326095 hasAuthorship W4387326095A5087420317 @default.
• W4387326095 hasAuthorship W4387326095A5092999109 @default.
• W4387326095 hasBestOaLocation W43873260951 @default.
• W4387326095 hasConcept C121608353 @default.
• W4387326095 hasConcept C126322002 @default.
• W4387326095 hasConcept C2776151105 @default.
• W4387326095 hasConcept C2779384505 @default.
• W4387326095 hasConcept C2780259306 @default.
• W4387326095 hasConcept C29730261 @default.
• W4387326095 hasConcept C526805850 @default.
• W4387326095 hasConcept C71924100 @default.
• W4387326095 hasConcept C98274493 @default.
• W4387326095 hasConceptScore W4387326095C121608353 @default.
• W4387326095 hasConceptScore W4387326095C126322002 @default.
• W4387326095 hasConceptScore W4387326095C2776151105 @default.
• W4387326095 hasConceptScore W4387326095C2779384505 @default.
• W4387326095 hasConceptScore W4387326095C2780259306 @default.
• W4387326095 hasConceptScore W4387326095C29730261 @default.
• W4387326095 hasConceptScore W4387326095C526805850 @default.
• W4387326095 hasConceptScore W4387326095C71924100 @default.
• W4387326095 hasConceptScore W4387326095C98274493 @default.
• W4387326095 hasIssue "3" @default.

• next